{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:06:27Z","timestamp":1784945187985,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP15am0301004"],"award-info":[{"award-number":["JP15am0301004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19am0401003"],"award-info":[{"award-number":["JP19am0401003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15J05689"],"award-info":[{"award-number":["15J05689"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.omtn.2025.102468","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T07:32:34Z","timestamp":1738395154000},"page":"102468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of chemical modification on the exon-skipping activity of heteroduplex oligonucleotides"],"prefix":"10.1016","volume":"36","author":[{"given":"Takenori","family":"Shimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakatsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotomi","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-3263","authenticated-orcid":false,"given":"Takanori","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-6812","authenticated-orcid":false,"given":"Satoshi","family":"Obika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102468_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-Approved Oligonucleotide Therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nn.4508","article-title":"Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy","volume":"20","author":"Corey","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtn.2025.102468_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.omtn.2025.102468_bib4","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102468_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2021.0039","article-title":"Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives","volume":"32","author":"Synofzik","year":"2022","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2025.102468_bib6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102468_bib7","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","article-title":"Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides","volume":"90","author":"Dominski","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102468_bib8","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.mt.6300095","article-title":"Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript","volume":"15","author":"Wilton","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/mt.2008.205","article-title":"Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms","volume":"17","author":"Aartsma-Rus","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib10","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1093\/nar\/gku512","article-title":"Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in\u00a0vitro","volume":"42","author":"Shimo","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102468_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/hum.2013.234","article-title":"Development of therapeutic splice-switching oligonucleotides","volume":"25","author":"Disterer","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-4939-7374-3_10","article-title":"Designing Effective Antisense Oligonucleotides for Exon Skipping","volume":"1687","author":"Shimo","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2025.102468_bib13","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.gt.3302313","article-title":"Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells","volume":"11","author":"Aartsma-Rus","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ymthe.2006.05.017","article-title":"Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice","volume":"14","author":"Roberts","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20080013","article-title":"Splice-switching efficiency and specificity for oligonucleotides with locked nucleic acid monomers","volume":"412","author":"Guterstam","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.omtn.2025.102468_bib16","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/mt.2008.85","article-title":"An Endogenous TNF-\u03b1 Antagonist Induced by Splice-switching Oligonucleotides Reduces Inflammation in Hepatitis and Arthritis Mouse Models","volume":"16","author":"Graziewicz","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib17","doi-asserted-by":"crossref","first-page":"34049","DOI":"10.1039\/C7RA06091B","article-title":"Antisense oligonucleotide modified with serinol nucleic acid (SNA) induces exon skipping in mdx myotubes","volume":"7","author":"Le","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.omtn.2025.102468_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.omtn.2017.09.002","article-title":"Rational Design of Short Locked Nucleic Acid-Modified 2\u2032-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In\u00a0Vitro","volume":"9","author":"Le","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102468_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197373","article-title":"Construction of a tri-chromatic reporter cell line for the rapid and simple screening of splice-switching oligonucleotides targeting DMD exon 51 using high content screening","volume":"13","author":"Shimo","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102468_bib20","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1039\/C8CC09648A","article-title":"Enhancement of exon skipping activity by reduction in the secondary structure content of LNA-based splice-switching oligonucleotides","volume":"55","author":"Shimo","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.omtn.2025.102468_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bmcl.2018.12.005","article-title":"Synthesis of 2\u2032-O-(N-methylcarbamoylethyl) 5-methyl-2-thiouridine and its application to splice-switching oligonucleotides","volume":"29","author":"Masaki","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.omtn.2025.102468_bib22","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1038\/s41598-019-42523-0","article-title":"Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in\u00a0vitro","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102468_bib23","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.3390\/ijms22073526","article-title":"Design and In\u00a0Vitro Evaluation of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, and Guanidine-Bridged Nucleic Acids","volume":"22","author":"Shimo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102468_bib24","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1038\/s41467-022-31636-2","article-title":"An LNA-amide modification that enhances the cell uptake and activity of phosphorothioate exon-skipping oligonucleotides","volume":"13","author":"Baker","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102468_bib25","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1021\/ja102635c","article-title":"Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands","volume":"132","author":"Nakagawa","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102468_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102468_bib27","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.1039\/C3CC46067C","article-title":"Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry","volume":"49","author":"Shabanpoor","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.omtn.2025.102468_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/nar\/gku1256","article-title":"Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy","volume":"43","author":"Shabanpoor","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102468_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymthe.2017.10.004","article-title":"Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy","volume":"26","author":"Jirka","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24061180","article-title":"Oligonucleotide(-)Palladacycle Conjugates as Splice-Correcting Agents","volume":"24","author":"Hande","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102468_bib31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1089\/nat.2020.0907","article-title":"Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides","volume":"31","author":"Tone","year":"2021","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2025.102468_bib32","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112546119","article-title":"Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy","volume":"119","author":"Lim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102468_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2018.0747","article-title":"Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment","volume":"29","author":"Gait","year":"2019","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2025.102468_bib34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/gene.1039","article-title":"Achieving efficient delivery of morpholino oligos in cultured cells","volume":"30","author":"Morcos","year":"2001","journal-title":"Genesis"},{"key":"10.1016\/j.omtn.2025.102468_bib35","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/hmg\/ddg196","article-title":"Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle","volume":"12","author":"Gebski","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102468_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jgm.838","article-title":"Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide","volume":"8","author":"Fletcher","year":"2006","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtn.2025.102468_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.bcp.2004.03.040","article-title":"Increased uptake of antisense oligonucleotides by delivery as double stranded complexes","volume":"68","author":"Astriab-Fisher","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102468_bib38","doi-asserted-by":"crossref","first-page":"7969","DOI":"10.1038\/ncomms8969","article-title":"DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing","volume":"6","author":"Nishina","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102468_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.72","article-title":"Chimeric Antisense Oligonucleotide Conjugated to alpha-Tocopherol","volume":"4","author":"Nishina","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102468_bib40","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","article-title":"Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS","volume":"39","author":"Nagata","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102468_bib41","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ymthe.2020.10.017","article-title":"Efficient Gene Suppression by DNA\/DNA Double-Stranded Oligonucleotide In\u00a0Vivo","volume":"29","author":"Asami","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib42","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1093\/nar\/gki918","article-title":"Nearest-neighbor thermodynamics of deoxyinosine pairs in DNA duplexes","volume":"33","author":"Watkins","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102468_bib43","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.omtn.2020.11.022","article-title":"Separation-related rapid nuclear transport of DNA\/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking","volume":"23","author":"Ono","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102468_bib44","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0960-8966(99)00010-3","article-title":"Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides","volume":"9","author":"Wilton","year":"1999","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102468_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1073\/pnas.98.1.42","article-title":"Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse","volume":"98","author":"Mann","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102468_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.mt.6300006","article-title":"The influence of antisense oligonucleotide length on dystrophin exon skipping","volume":"15","author":"Harding","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102468_bib47","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2025.102468_bib48","doi-asserted-by":"crossref","first-page":"7530","DOI":"10.1038\/s41467-024-48204-5","article-title":"Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model","volume":"15","author":"Hasegawa","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102468_bib49","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1093\/nar\/gkz492","article-title":"Highly efficient silencing of microRNA by heteroduplex oligonucleotides","volume":"47","author":"Yoshioka","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102468_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93666-y","article-title":"Effective silencing of miR-126 after ischemic stroke by means of intravenous alpha-tocopherol-conjugated heteroduplex oligonucleotide in mice","volume":"11","author":"Suzuki","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102468_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/nat.2022.0063","article-title":"Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy","volume":"33","author":"van Deutekom","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2025.102468_bib52","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3389\/fgene.2019.01249","article-title":"Consequences of Making the Inactive Active Through Changes in Antisense Oligonucleotide Chemistries","volume":"10","author":"Zaw","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.omtn.2025.102468_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2016.02.007","article-title":"Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability\u00a0of cholesterol-conjugated antisense oligonucleotides","volume":"226","author":"Wada","year":"2016","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.omtn.2025.102468_bib54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2025.102468_bib55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2105-13-134","article-title":"Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction","volume":"13","author":"Ye","year":"2012","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.omtn.2025.102468_bib56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s10038-017-0400-0","article-title":"A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR\/Cas9 and evaluation of antisense-mediated exon skipping","volume":"63","author":"Shimo","year":"2018","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102468_bib57","series-title":"R: A Language and Environment for Statistical Computing","author":"Team","year":"2020"},{"key":"10.1016\/j.omtn.2025.102468_bib58","series-title":"RStudio: Integrated Development for R","author":"Team","year":"2020"},{"key":"10.1016\/j.omtn.2025.102468_bib59","author":"Pohlert"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:45:06Z","timestamp":1744508706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2162253125000228"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102468","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of chemical modification on the exon-skipping activity of heteroduplex oligonucleotides","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102468"}}